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S U M M A R Y
Background: Rotavirus infection is the most common cause of severe gastroenteritis in children
worldwide. New rotavirus vaccines are not currently used in the ﬁve countries that make up the Central
Asian region. Three of these countries, Kazakhstan, Uzbekistan, and Kyrgyzstan, have a combined total
population of 48 million and an estimated 1 million annual births.
Methods: We conducted prospective hospital-based surveillance for rotavirus diarrhea in three Central
Asian countries (Kazakhstan, Uzbekistan, and Kyrgyzstan) during 2005–2009 to estimate the burden of
rotavirus. We calculated the proportion of rotavirus among children aged <5 years hospitalized with
acute diarrhea and estimated numbers of rotavirus-associated deaths, hospitalizations, outpatient visits,
and home care episodes.
Results: Of 20 780 children hospitalized with diarrhea and enrolled in the study, 26% (95% conﬁdence
interval (CI) 25–27) were positive for rotavirus antigen by ELISA. On an annual basis, 4007 (2.6 per 1000
child-years) rotavirus hospitalizations occur in Kazakhstan, 5491 (2.1 per 1000 child-years) in
Uzbekistan, and 3883 (6.8 per 1000 child-years) in Kyrgyzstan. Rotavirus is also estimated to cause 68
(0.04 per 1000 child-years) deaths in children aged <5 years in Kazakhstan, 662 (0.25 per 1000 child-
years) in Uzbekistan, and 156 (0.27 per 1000 child-years) in Kyrgyzstan.
Conclusion: This study presents an epidemiological picture of rotavirus disease in Central Asia and
illustrates a substantial rotavirus burden, which is preventable with rotavirus vaccination.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Rotavirus is the leading cause of severe childhood gastroenteri-
tis in both developed and developing countries.1,2 An estimated 2.3
million hospitalizations and approximately 527 000 deaths in
children aged <5 years are caused by rotavirus3 annually
worldwide, but most rotavirus-associated deaths occur in low-
income countries.2 Approximately 95% of children are infected
before 3–5 years of age, and the highest incidence occurs between
6 and 24 months of age.4 Rotavirus can also affect adults and is
often manifested in subclinical forms.5
The possibility of an effective prevention of rotavirus infection
through improvements in hygiene and sanitary conditions is* Corresponding author. Tel.: +998 97 7176988; fax: +998 71 2245107.
E-mail address: renatlatip@gmail.com (R. Latipov).
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rotavirus infection, and two licensed rotavirus vaccines have been
available on the world market since 2006.9 Their efﬁcacy and
safety have been demonstrated in large-scale clinical trials,
although efﬁcacy estimates for these vaccines have differed
between industrialized and developing countries. In Europe, the
efﬁcacy against severe rotavirus diarrhea reached 90–98%,10,11
whereas studies conducted in several African and Asian countries
demonstrated an overall efﬁcacy of 39.3%12 and 48.3%,13 respec-
tively. At present, several countries have already introduced the
rotavirus vaccine into routine practice, and data on the effective-
ness of vaccines differ in developed and developing countries.
Thus, the effectiveness against severe disease was 86–94% in the
USA14 and 74% Austria,15 but data from Nicaragua demonstrate an
effectiveness of 58% against severe cases and 77% against very
severe disease.16 There are multiple explanatory reasons for the
lower efﬁcacy of rotavirus vaccines in the developing countries ofses. Published by Elsevier Ltd. All rights reserved.
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of maternal antibodies, co-administration with oral poliovirus
vaccine, breastfeeding, poorer nutritional status, and presence of
other enteric microorganisms in a child’s gut. Despite the lower
efﬁcacy in developing settings, the introduction of new rotavirus
vaccines into routine immunization in these settings may decrease
the rates of morbidity and mortality from diarrhea. Thus, the
World Health Organization’s (WHO) Strategic Advisory Group of
Experts (SAGE) on Immunization have recommended the inclusion
of rotavirus vaccines into national immunization programs
globally,17 and national policymakers need to decide whether to
introduce such a program. This decision must be based on local
information about rotavirus-speciﬁc mortality and morbidity.
Such information is available in several developing countries, but
knowledge about the epidemiology and burden of rotavirus
infection in the Central Asian region is still lacking. The ﬁve
Central Asian countries (Kazakhstan, Kyrgyzstan, Uzbekistan,
Turkmenistan, and Tajikistan) are highly populated and have a
warm and dry climate with a shortage of water resources.
Diarrheal disease is an important public health problem, and is
estimated to cause between 2% and 14% of deaths among children
under 5 years of age.18
We conducted our study in three Central Asian republics:
Kazakhstan, Kyrgyzstan, and Uzbekistan. These are newly inde-
pendent states with a combined population of 48 million and an
estimated 1 million annual births. The under-5 mortality rate
varies by country, but is estimated to be between 30 and 38 deaths
per 1000 live-births.19–21 Because of a common Soviet heritage, all
three countries have similar health care systems, though due to
different rates of economic development, Uzbekistan and Kyrgyz-
stan are classiﬁed by the World Bank as low-income countries
(USD 910 and USD 780 gross national income (GNI) per capita,
respectively), whereas Kazakhstan is an upper-middle income
economy (USD 6160 GNI per capita) (Table 1).22 Based on their GNI,
Uzbekistan and Kyrgyzstan are eligible for new vaccine assistance
from the GAVI Alliance, which only supports countries with a GNI
per capita below USD 1000.23
Knowing that routine childhood immunizations in these
countries are provided through the centrally managed national
program and that there is high vaccine coverage (coverage for the
third dose of diphtheria toxoid, tetanus toxoid and pertussis
vaccine (DTP3) at 1 year of age is 96–99%),24,25 it is possible that
rotavirus vaccination could be an effective tool in preventing
rotavirus infection in these settings. Hospital-based rotavirus
surveillance was initiated in Uzbekistan and Kyrgyzstan in 2005,
and the initial assessments of rotavirus burden in these countries
have been published.26,27 In Kazakhstan, however, similar
surveillance started in late 2007. This study presents new 2-year
data from Kazakhstan and reviewed and updated data from
Kyrgyzstan and Uzbekistan for the period 2007–2009. We describe
country-speciﬁc results and present the burden of rotavirus
disease from a regional perspective in order to help the nationalTable 1
Main characteristics of the three Central Asian republics included in the study
Country GNI per
capita,
USDa
Population,
millionsb
Birth cohort,
thousandsc
Under-5
mortality
ratec
Kazakhstan 6140 15.7 349 30.2
Uzbekistan 910 27.3 553 38.0
Kyrgyzstan 740 5.2 120 38.4
GNI, gross national income; USD, US dollars.
a The World Bank country data 2010; available at: http://data.worldbank.org/.
b World Health Organization Statistical Information System (WHOSIS); available
at: http://www.who.int/whosis/en/.
c UNICEF.19–21and regional decision-making on the introduction of rotavirus
vaccine.
2. Methods
2.1. Sentinel sites and study period
We used an identical study protocol in all countries, which was
developed in accordance with the WHO’s generic protocol for
rotavirus hospital-based surveillance.28 In each country, we chose
two sentinel infectious diseases hospitals admitting children with
acute gastroenteritis. In Central Asia, health care systems are quite
similar across countries, with all children with diarrhea being
exclusively treated in infectious disease hospitals. In urban areas,
children are treated in city hospitals for infectious diseases,
whereas children from semi-urban or rural areas are admitted to
regional or district hospitals for infectious diseases. This hierarchy
of hospitals for diarrhea patients is similar across the study
countries, and in order to increase comparability of data across
countries, sentinel sites were chosen to represent urban and semi-
urban/rural areas).
2.2. Case deﬁnition and sampling
The case deﬁnition and inclusion/exclusion criteria were based
on the WHO’s generic protocol for rotavirus hospital-based
surveillance.28 All children <5 years of age with acute gastroen-
teritis admitted to participating hospitals within 7 days of onset
were eligible for the study. Acute gastroenteritis was deﬁned by
the physician who admitted the child for hospitalization. Children
with other acute co-morbidities or chronic diarrhea were excluded
in each country, while every third eligible child was enrolled in an
urban hospital and every second one in a hospital located in a semi-
urban/rural area. Data collected from each child included
information on the patient’s age, admission and discharge dates,
and duration of symptoms. Written informed consent was
obtained from the parent(s) of each enrolled patient.
2.3. Sample collection and testing
Stool samples were obtained from each enrolled child within
24 h after admission to hospital and were kept at 4 8C prior to ELISA
testing. In Kazakhstan, samples were processed and stored in the
Department of Virology of the Republican Center for State Sanitary
and Epidemiological Control in Almaty and in the Virology
Laboratory of Infectious Diseases in Karaganda. For rotavirus
detection, we used commercial ELISA assays: RIDASCREEN1
Rotavirus (R-Biopharm, Darmstadt, Germany) in Kazakhstan and
DAKO IDEIA Rotavirus (DAKO Diagnostics Ltd, Glostrup, Denmark)
in Uzbekistan and Kyrgyzstan. Diagnostic and stool sample
processing procedures were the same in all countries and are
described in detail elsewhere.26,27
2.4. Data management and analysis
All collected data were entered into an electronic database.
Characteristics of the rotavirus-positive and rotavirus-negative
patients and differences between countries were compared using
the Chi-square test and t-test. To estimate the cumulative risk of
rotavirus-associated hospitalizations and deaths, we applied
surveillance data to the nationally reported number of gastroen-
teritis hospitalizations and to WHO diarrhea-speciﬁc mortality
estimates in children <5 years of age.19–21 The WHO’s diarrhea
estimates were used because national diarrhea-speciﬁc mortality
rates were not available. Due to a lack of data about outpatient
(polyclinic) visits and number of mild (home care) cases, the
Table 2
Number of enrolled children under 5 years of age with acute gastroenteritis hospitalized in sentinel hospitals, and proportion of rotavirus-positive cases
Year Kyrgyzstan Uzbekistan Kazakhstan Total number
No. enrolled % RV positive
(95% CI)
No. enrolled % RV positive
(95% CI)
No. enrolled % RV positive
(95% CI)
No. enrolled % RV positive
(95% CI)
2005 1021 24 (21–27) 1597 33 (31–36) 2618 30 (28–31)
2006 1989 26 (24–28) 1940 26 (25–28) 3929 26 (25–28)
2007 746 26 (23–30)a 1809 24 (22–26)b 110 29 (20–38)c 2665 25 (23–27)
2008 1882 21 (19–23) 2286 26 (24–28)b 1763 33 (31–35) 5931 26 (25–27)
2009 1810 25 (23–27) 2534 22 (20–24) 1293 26 (24–29) 5637 24 (23–25)
Total 7448 24 (23–25) 10 166 26 (25–27) 3166 30 (28–32) 20 780 26 (25–27)
RV, rotavirus; CI, conﬁdence interval.
a Data do not include period from June to July 2008.
b Data do not include period from December 2007 to May 2008.
c Data presented only for December 2007.
Figure 1. Percentage of rotavirus-positive cases by month in children aged <5 years
in three Central Asian republics (KAZ, Kazakhstan; UZB, Uzbekistan; KGZ,
Kyrgyzstan), 2005–2009 (*aggregate data for 2005–2009 presented for UZB and
KGZ, and 2008–2009 data presented for KAZ).
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estimated on the basis of the approach described by Parashar et al.1
Based on this, we assumed that for every hospitalized rotavirus
case, there are 8 (range 5–10) outpatient visits associated with
rotavirus diarrhea, and for each case requiring outpatient
(polyclinic) care, there are 4 (range 3–5) mild cases of rotavirus
diarrhea requiring home care only.
3. Results
3.1. Hospital surveillance
A total of 20 780 hospitalized children with acute gastroenteri-
tis in all three countries during the surveillance period were
enrolled in the study. Of these, 10 166 (49%) were enrolled in
Uzbekistan, 7448 (36%) in Kyrgyzstan, and 3166 (15%) in
Kazakhstan. Stool samples were obtained from all enrolled
children, and 5398 (26%, 95% conﬁdence interval (CI) 25–27)
were rotavirus-positive by ELISA (Table 2). The overall proportions
of rotavirus-positive cases did not differ substantially between
countries, with 24% (95% CI 23–25) detected in Kyrgyzstan, 26%
(95% CI 25–27) in Uzbekistan, and 30% (95% CI 28–32) in
Kazakhstan. Nevertheless, these slight differences in detection
rates between countries were still statistically signiﬁcant (p <
0.05) due to a large number of observations. However, annual
detection rates ﬂuctuated over the study period in Kyrgyzstan and
Kazakhstan, although these ﬂuctuations were within the 95% CI. In
Uzbekistan, the rotavirus detection rate slightly decreased over a
5-year period from 33% (95% CI 31–36) to 22% (95% CI 20–24),
which may have been related to sampling errors.Table 3
Characteristics of rotavirus-positive children under 5 years of age with acute gastroen
Characteristic Kyrgyzstan
(n = 1815)
Uzbek
(n = 26
Age groups, months, n (%)
0–2 98 (5.4) 74 (2.8
3–5 210 (11.6) 242 (9
6–11 699 (38.5) 824 (3
12–23 643 (35.4) 1048 (
24–35 103 (5.7) 266 (1
36–47 40 (2.2) 136 (5
48–59 22 (1.2) 42 (1.6
Mean age, months (SD) 12.5 (8.9) 15.2 (1
Sex
Male, n (%) 1040 (57.3) 1517 (
Frequency of
Fever, n (%) 1290 (71.1) 2358 (
Vomiting, n (%) 989 (54.5) 1991 (
Mean hospitalization duration, days (SD) 4.9 (1.9) 5.8 (2.
SD, standard deviation.
a p-Value of the difference by t-test or Chi-square test.The mean age of rotavirus-positive cases was 14.1 months
(standard deviation (SD) 9.9) for all children in the three countries
(Table 3). The lowest mean age was detected in Kyrgyzstan (12.5,
SD 8.9) and the highest in Uzbekistan (15.2, SD 10.4). Rotavirus was
detected in children of all age groups, but those under 2 years of
age accounted for 86.2% of all cases (Table 3). About half (48.4%) of
the hospitalized children with rotavirus diarrhea were below the
age of 1 year. No signiﬁcant differences in the proportion of
children <1 year old were found between the countries.teritis hospitalized in sentinel hospitals
istan
32)
Kazakhstan
(n = 951)
Total number
(n = 5398)
p-Value of
differencea
) 67 (7.0) 239 (4.4) p < 0.0001
.2) 105 (11.0) 557 (10.3)
1.3) 292 (30.7) 1815 (33.6)
39.8) 349 (36.7) 2040 (37.8)
0.1) 96 (10.1) 465 (8.6)
.2) 29 (3.0) 205 (3.8)
) 13 (1.4) 77 (1.4)
0.4) 13.9 (10.2) 14.1 (9.9) p < 0.0001
57.6) 550 (57.8) 3107 (57.6) p > 0.05
89.6) 823 (86.5) 4471 (82.8) p < 0.0001
75.6) 787 (82.8) 3767 (69.8) p < 0.0001
1) 5.3 (2.1) 5.6 (2.1) p > 0.05
Figure 2. Percentage of rotavirus-positive cases by age and by month in children
aged <5 years in three Central Asian republics, 2005–2009 (*aggregate data for all
three countries (Uzbekistan, Kazakhstan, and Kyrgyzstan) presented; **aggregate
data for 2005–2009 presented for Uzbekistan and Kyrgyzstan, and 2008–2009 data
presented for Kazakhstan).
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infections were more common from October through March.
The major peak was detected during October–November in all
three countries, followed by a second peak in February that was
only observed in Uzbekistan and Kazakhstan (Figure 1). This
seasonality pattern became more pronounced with increasing age
(Figure 2), with the second peak being observed more among
children aged 24 months and older. We did not ﬁnd a clear
statistical association between the second peak and other possible
confounders such as gender or site.
In all rotavirus-positive patients, a fever was detected in 4471
(82.8%) and vomiting in 3767 (69.8%) children. Interestingly, the
frequency of fever and vomiting was the lowest in Kyrgyzstan
(71.1% and 54.5%, respectively) among all countries, suggesting
that cases with milder forms of diarrhea may have been
hospitalized there more frequently.
3.2. Disease burden
According to the ministries of health of each country, the total
registered number of gastroenteritis hospitalizations in childrenTable 4
Rotavirus disease burden among children under 5 years of age in three Central Asian r
Kazakhstan Kyrgyzstan
RV deathsa
n, thousands (range) 0.068 (0.063–0.072) 0.156 (0.15
Incidence rateb 0.04 0.27 
Cumulative riskc 1:5132 1:769 
RV hospitalizationsd
n, thousands (range) 4.0 (3.7–4.3) 3.9 (3.7–4.0
Incidence rateb 2.6 6.8 
Cumulative riskc 1:87 1:31 
RV outpatient clinic visitse
n, thousands (range) 32.5 (18.7–42.7) 31.0 (18.6–
Incidence rateb 20.7 54.5 
Cumulative riskc 1:11 1:4 
RV home care casesf
n, thousands (range) 130.0 (56.1–213.7) 124.2 (55.8
Incidence rateb 82.9 218.1 
Cumulative riskc 1:3 1:1 
RV, rotavirus
a Number of rotavirus deaths per year.
b Incidence rate per 1000 child-years.
c Cumulative under 5-year risk per annual birth cohort.
d Number of rotavirus hospitalizations among children aged <5 years per year.
e Number of rotavirus outpatient clinic visits per year.
f Number of rotavirus home care cases per year.<5 years was 13 357 in Kazakhstan, 21 120 in Uzbekistan, and
16 178 in Kyrgyzstan in 2009. By applying the rotavirus proportion
from the surveillance data of each country, we estimated 4007 (2.6
per 1000 child-years) annual rotavirus hospitalizations in Kazakh-
stan, 5491 (2.1 per 1000 child-years) in Uzbekistan, and 3883 (6.8
per 1000 child-years) in Kyrgyzstan (Table 4). This corresponds to
one in every 87 children in Kazakhstan, one in every 101 in
Uzbekistan, and one in every 31 in Kyrgyzstan being hospitalized
for rotavirus gastroenteritis by the age of 5 years. In total, we
estimated 13 381 (2.8 per 1000 child-years) hospitalizations that
are attributable to rotavirus in the three countries combined,
which suggests that one in every 82 children in the region is
hospitalized for rotavirus gastroenteritis by age 5.
Since the proportion of diarrhea-associated deaths dropped
dramatically in these countries recently (from 16.5% in 2004 to 2%
in 2008 in Kazakhstan, from 22.3% to 12% in Uzbekistan, and from
19.9% to 14% in Kyrgyzstan29), we used the latest available
international estimates of under-5 deaths in each country to
calculate rotavirus-attributable deaths. By applying the WHO’s
proportion of under-5 deaths attributable to diarrhea,29 we
estimated that rotavirus caused 68 (0.04 per 1000 child-years)
deaths annually in children <5 years in Kazakhstan, 156 (0.27 per
1000 child-years) in Kyrgyzstan, and 662 (0.25 per 1000 child-
years) in Uzbekistan (Table 4). This translates to a risk of one in
5132, 769, and 835 children dying from rotavirus before 5 years of
age in Kazakhstan, Kyrgyzstan, and Uzbekistan, respectively. In
total, 886 child deaths each year are attributable to rotavirus in
these three Central Asian republics, suggesting that one child in
approximately 1153 dies from rotavirus before 5 years of age in the
region. These estimates of rotavirus-related mortality are consid-
erably lower than previously reported.26,27
Because no country-speciﬁc data on outpatient visits or home
care episodes of acute gastroenteritis among children aged <5
years were available, we estimated these events using a previously
described approach.30 Based on this approach, 32 506 annual
rotavirus outpatient clinic visits were calculated to occur in
Kazakhstan, 43 928 in Uzbekistan, and 31 064 in Kyrgyzstan,
amounting to 107 498 outpatient clinic visits per year. The number
of mild (home care) cases of rotavirus diarrhea was estimated at
130 024, 175 712, and 124 256 annually in Kazakhstan, Uzbekistan,
and Kyrgyzstan, respectively, suggesting that 429 992 mild cases
may occur each year in the three Central Asian republics. In otherepublics, 2009
 Uzbekistan Total
0–0.163) 0.662 (0.637–0.688) 0.886 (0.850–0.923)
0.25 0.18
1:835 1:1153
) 5.5 (5.3–5.7) 13.4 (12.9–13.8)
2.1 2.8
1:101 1:82
40.4) 43.9 (26.4–57.0) 107.4 (63.7–140.2)
17.1 22.8
1:13 1:10
–202.2) 175.7 (79.2–285.1) 429.9 (191.1–701.0)
68.2 91.2
1:3 1:2
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rotavirus before the age of 5 years, and one in two children will
have at least one mild episode of rotavirus diarrhea before the age
of 5 years.
4. Discussion
This study presents data on rotavirus epidemiology and burden
in three Central Asian countries, which in terms of population and
total area represent more than 90% of the region. According to the
WHO,31 Central Asia is a region with high rotavirus morbidity and
low mortality. Countries included in this study are located in the
same climatic zone and have similar health systems, with a high
population coverage (>95%) for primary health care services that
include a well-developed immunization system. Routine vaccina-
tions in Central Asia are compulsory and free for the population. In
Kazakhstan, the immunization program is fully government-
funded, whereas Uzbekistan and Kyrgyzstan are eligible for
vaccine support from the GAVI Alliance.
In this study, we summarized long-term data obtained during
active hospital-based surveillance, which were organized using an
identical study protocol and allowed for comparisons between
countries. We estimated 13 381 rotavirus hospitalizations
annually in the three countries, with a cumulative hospitalization
risk of 1:101 in Uzbekistan, 1:87 in Kazakhstan, and 1:31 in
Kyrgyzstan. The risk of rotavirus hospitalization in Central Asia is
different from that in other parts of the world. For example, in
industrialized countries, the cumulative hospitalization risk for
children by the age of 5 years is higher: one in 54 children in
Europe32 and one in 73 children in the USA.33 The risk of rotavirus
hospitalization is usually lower in developing countries, but we
believe that for Uzbekistan and Kazakhstan, the true risk for
rotavirus hospitalization may be higher than that calculated in our
study. This is because these countries do not register all
hospitalized cases of gastroenteritis, and due to substantial
underreporting, the extent of diarrhea hospitalizations is not
captured in the national statistics. The higher hospitalization risk
in Kyrgyzstan compared to the other two countries is interesting,
as it could not be explained by climatic or geographical differences.
It is possible that Kyrgyz hospitals are interested in increasing the
number of hospitalized cases since this affects the ﬁnancing of
hospitals by the government.26 The underestimation was probably
the cause of the low average mortality rates that were estimated:
0.27 deaths per 1000 child-years in Kyrgyzstan and 0.25 deaths per
1000 child-years in Uzbekistan. These rates were signiﬁcantly
lower than such estimates presented by Chandran et al. for low and
lower-middle income countries (1.38 and 0.53 per 1000 children,
respectively).34 But for Kazakhstan, we estimated a rotavirus
mortality (0.04 per 1000) that corresponds to upper-middle
income countries (0.069 per 1000).34
In Central Asia, rotavirus was detected in an average 26% of
stool samples collected from hospitalized patients with diarrhea,
with slight variations in detection rates between countries. The
highest detection rate was observed in Kazakhstan (30%), followed
by Uzbekistan (26%) and Kyrgyzstan (24%). Nonetheless, rotavirus
detection rates can ﬂuctuate annually and considering that we only
conducted surveillance for 2 years in Kazakhstan, the high
rotavirus detection rate there could also be explained by a shorter
surveillance period compared to the other two countries. The
rotavirus proportion among all causes of gastroenteritis varies by
country and over time. According to published reviews, the
average detection rate of rotaviruses among children aged less
than 5 years increased worldwide from 20% in 1986–19991 to 29%
in 1990–2004,3 and to 40% in 2001–2008.31 Our results could be
compared with data provided by Mirzayeva et al.,35 who reported
on rotavirus surveillance conducted in several countries from theWHO European Region using a similar protocol.36 These data from
2007 show higher rotavirus detection rates by ELISA in the Ukraine
(42%), Georgia (40%), and Tajikistan (39%). Another study from
Russia37 reported a rotavirus proportion of 44% established by PCR,
which is more sensitive compared to ELISA. Variations in rotavirus
proportions cannot only be attributed to economic and climatic
differences between these countries, especially because Tajikistan
is a low-income country in Central Asia bordering Kyrgyzstan and
Uzbekistan. It is likely that hospitalization patterns of patients
with diarrhea in each country, as well as deﬁciencies associated
with specimen collection, storage and testing, could have
inﬂuenced the ﬁndings. It is also possible that variations in
diarrhea deﬁnitions used by hospital physicians could have
contributed to lower rotavirus rates in the study countries.
Therefore, it is likely that the true rotavirus proportion in countries
included in this study is higher than observed.
The peak of rotavirus infection is usually observed between the
ages of 9 and 23 months.1,38,39 In our analysis, we observed a
similar age distribution among rotavirus cases in all three
countries, with about half the cases (48.4%) infected during the
ﬁrst year of life, and 86.2% were under the age of 2 years. Such
rotavirus prevalence in young children is common for developing
countries.38 We also found that 7.0% of all rotavirus cases in
Kazakhstan, 5.4% in Kyrgyzstan, and 2.8% in Uzbekistan were in
infants under 3 months of age, despite the high breastfeeding rates
reported in these countries (95%). Rotavirus infection in infants at
that age is fairly uncommon due to protection by maternal
antibodies acquired in utero or through breastfeeding.40,41
However, factors such as malnutrition and other enteric infections
can affect a child’s immune response and thus contribute to higher
rates of rotavirus infection in infancy. At the same time, recent
rotavirus vaccine efﬁcacy studies in Africa12 and Asia13 have shown
low levels of vaccine efﬁcacy due to young age at vaccination and
high levels of residual maternal antibodies. The high proportion of
positive cases among children under 3 months old in Central Asia
could potentially be in favor of more successful vaccination in this
region.
The seasonality of rotaviruses varies with increasing longitude,
with disease peaks being less pronounced in the equatorial
countries.42–45 Globally, rotavirus is certainly more common in the
cooler and drier months46 of the year and manifests itself more
often in the autumn and winter. Seasonality in the Central Asian
region shows a common picture for rotaviruses, with a character-
istic increase in cases during autumn and winter months.
Our study has a number of limitations. The results presented are
only based on data received from sentinel hospitals, which may not
be fully representative of the entire country. We did not use a
clinical severity score to classify hospitalized cases of diarrhea and
assumed that all hospitalized cases were the most severe cases. We
did not have the resources to conduct surveillance for cases with
moderate or mild diarrhea treated in outpatient clinics or at home,
so therefore, the estimated rotavirus burden associated with these
cases is based on previous assumptions.1
In conclusion, this study presents an epidemiologic picture of
rotavirus diseases in Central Asia and illustrates a substantial
rotavirus burden that is preventable by the use of rotavirus
vaccination. This data, in combination with information on the
cost-effectiveness of rotavirus vaccination, may be helpful for
national decision-makers who are planning preventive and control
measures in the involved countries.
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